Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | STAT5B | P51692 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 4/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859337 | 0.90 | ESR1 (0.39) | KMT2AF2ESR1PTPN11STAT5B | |
| SCHEMBL1857094 | 0.88 | F2 (0.40) | KMT2AF2NR1H2 | |
| SCHEMBL4014555 | 0.83 | KMT2A (0.44) | KMT2AESR1MMP13MMP2MMP12 | |
| SCHEMBL1866007 | 0.82 | PTPN11 (0.38) | PTPN11MMP13MMP2MMP12 | |
| SCHEMBL1859570 | 0.80 | MMP13 (0.38) | STAT5BMMP13MMP2MMP3 | |
| SCHEMBL1858294 | 0.79 | KMT2A (0.47) | KMT2AF2ESR1MMP13MEN1 | |
| SCHEMBL1855707 | 0.78 | F2 (0.40) | KMT2AF2NR1H2 | |
| SCHEMBL1861012 | 0.77 | TP53 (0.37) | F2MMP13MMP2NR1H2MMP3 | |
| SCHEMBL1864812 | 0.75 | PTGER1 (0.37) | KMT2AMEN1 | |
| SCHEMBL8752627 | 0.75 | KMT2A (0.56) | KMT2AF2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | KMT2A 2127/4885F2 2826/4885ESR1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.